Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies

References

• Amsden JR, Gubbins PO. 2017. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. Expert Opin Drug Metab Toxicol. 13(11):1135–1146.
   PubMed Web of Science ®Google Scholar
• Arnold TM, Dotson E, Sarosi GA, Hage CA. 2010. Traditional and emerging antifungal therapies. Proc Am Thorac Soc. 7(3):222–228.
   PubMedGoogle Scholar
• Bernal-Martínez L, Alcazar Fuoli L, Miguel-Revilla B, Carvalho A, Cuétara Garcia MS, Garcia-Rodriguez J, Cunha C, Gómez-García de la Pedrosa E, Gomez-Lopez A. 2019. High-resolution melting assay for genotyping variants of the CYP2C19 enzyme and predicting voriconazole effectiveness. Antimicrob Agents Chemother. 63(6):18. e02399-
   Web of Science ®Google Scholar
• Chen K, Zhang XL, Ke XY, Du GH, Yang KH, Zhai SD. 2018. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. Ther Drug Monit. 40(6):663–674.
   PubMed Web of Science ®Google Scholar
• Cheng L, Xiang RF, Liu F, Li YL, Chen HL, Yao P, Sun FJ, Xia PY. 2020. Therapeutic drug monitoring and safety of voriconazole in elderly patients. Int Immunopharmacol. 78(106078):106078.
   PubMed Web of Science ®Google Scholar
• Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SC, Sorrell TC. 2017. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 17(11):e344–e356.
   PubMed Web of Science ®Google Scholar
• Elewa H, El-Mekaty E, El-Bardissy A, Ensom MH, Wilby KJ. 2015. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet. 54(12):1223–1235.
   PubMed Web of Science ®Google Scholar
• Giri P, Naidu S, Patel N, Patel H, Srinivas NR. 2017. Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. Eur J Drug Metab Pharmacokinet. 42(4):677–688.
   PubMed Web of Science ®Google Scholar
• Hohmann N, Haefeli WE, Mikus G. 2016. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 12(5):479–497.
   PubMed Web of Science ®Google Scholar
• Hu L, Dai TT, Zou L, Li TM, Ding XS, Yin T. 2018. Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother. 62(12):e00955-18.
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 31(5):540–547.
   PubMed Web of Science ®Google Scholar
• Koehler P, Bassetti M, Kochanek M, Shimabukuro-Vornhagen A, Cornely OA. 2019. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect. 25(12):1501–1509.
   PubMed Web of Science ®Google Scholar
• Lamoureux F, Duflot T, Woillard JB, Metsu D, Pereira T, Compagnon P, Morisse-Pradier H, El Kholy M, Thiberville L, Stojanova J, et al. 2016. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents. 47(2):124–131.
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C. 2011. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs. 71(18):2405–2419.
   PubMed Web of Science ®Google Scholar
• Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. 2010. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 69(3):222–230.
   PubMed Web of Science ®Google Scholar
• Pearson MM, Rogers PD, Cleary JD, Chapman SW. 2003. Voriconazole: a new triazole antifungal agent. Ann Pharmacother. 37(3):420–432.
   PubMed Web of Science ®Google Scholar
• Phillips IR, Shephard EA. 2017. Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 13(2):167–181.
   PubMed Web of Science ®Google Scholar
• Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 31(6):731–741.
   PubMed Web of Science ®Google Scholar
• Saad AH, DePestel DD, Carver PL. 2006. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 26(12):1730–1744.
   PubMed Web of Science ®Google Scholar
• Sachse C, Ruschen S, Dettling M, Schley J, Bauer S, Müller-Oerlinghausen B, Roots I, Brockmöller J. 1999. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: Allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther. 66(4):431–438.
   PubMed Web of Science ®Google Scholar
• Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. 2019. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 51(3):247–265.
   PubMed Web of Science ®Google Scholar
• Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. 2013. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther. 94(5):601–609.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 45(7):649–663.
   PubMed Web of Science ®Google Scholar
• Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. 2009. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 49(2):196–204.
   PubMed Web of Science ®Google Scholar
• Woolsey SJ, Beaton MD, Choi YH, Dresser GK, Gryn SE, Kim RB, Tirona RG. 2016. Relationships between endogenous plasma biomarkers of constitutive cytochrome P450 3A activity and single-time-point oral midazolam microdose phenotype in healthy subjects. Basic Clin Pharmacol Toxicol. 118(4):284–291.
   PubMed Web of Science ®Google Scholar
• Yamada T, Mino Y, Naito T, Kawakami J. 2019. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients. J Infect Chemother. 25(12):1019–1025.
   PubMed Web of Science ®Google Scholar
• Yamazoe Y, Yamada T, Nagata K. 2020. Prediction and characterization of CYP3A4-mediated metabolisms of azole fungicides: an application of the fused-grid template* system. Food Saf (Tokyo)). 8(2):34–51.
   PubMedGoogle Scholar
• Yan M, Wu ZF, Tang D, Wang F, Xiao YW, Xu P, Zhang BK, Liu YP, Xiang DX, Banh HL. 2018. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 108:60–64.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK, Jr, Thakker DR. 2008. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 36(6):1119–1125.
   PubMed Web of Science ®Google Scholar
• Zeng G, Wang L, Shi L, Li H, Zhu M, Luo J, Zhang Z. 2020. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms. Eur J Clin Pharmacol. 76(4):515–523.
   PubMed Web of Science ®Google Scholar
• Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 9(4):310–322.
   PubMed Web of Science ®Google Scholar
• Zhou L, Sharma P, Yeo KR, Higashimori M, Xu H, Al-Huniti N, Zhou D. 2019. Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling. Eur J Pharm Sci. 139(105061):105061.
   PubMed Web of Science ®Google Scholar